A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER
Details
Age
Adult
Type of Study
Treatment
Locations
University of Colorado Hospital
Principal Investigator
David Camidge, MD, PhD
Study ID
Protocol Number: 21-3772
More information available at ClinicalTrials.gov: NCT04077099
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers